Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Study ID
NCT05772624
Phase
PHASE2
Status
Unknown

Conditions

  • Efficacy, Self
  • Safety Issues

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to prove the efficacy and safety of low dose nivolumab (40mg as the lowest available presentation) in combination with AVD (adriamycin,vinblastine sulfate and dacarbazine) as frontline treatment for classic Hodgkin's lymphoma.

Key Dates

First listed
Mar 16, 2023
Start date
Feb 13, 2023
Status verified
Mar 2023
Primary completion
Mar 1, 2024
Completion
Jun 1, 2024

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LowN-AVD
    classic Hodgkin's lymphoma patients receiving low dose nivolumab in combination with AVD

Primary Outcome Measure

To determine general response [ Time Frame: Six weeks after completion of therapy. ]

Central Contacts

Related Studies